Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other ...

Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Novo Nordisk NVO recently underwent a major leadership transition, as Lars Fruergaard Jørgensen stepped down as CEO on Aug. 7 ...

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be unaffected.

Johannesberg: Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's ...

Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes ...

Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly for allegedly bribing and ...